Jiangsu Hengrui Pharmaceuticals (01276) was oversubscribed 454.85 times in its public offering with a maximum price limit.

Jiangsu Hengrui Pharmaceuticals (01276) announced the results of the distribution. The company globally issued approximately 224.5 million shares, with 21.50% allocated for public offering in Hong Kong and 78.50% for international offering. The issue price per share is HK$44.05, with net proceeds from the global offering of approximately HK$9.7473 billion. Trading of H shares is expected to begin on the Hong Kong Stock Exchange on Friday, May 23, 2025, at 9:00 AM. The public offering in Hong Kong was oversubscribed by 454.85 times, while the international offering was oversubscribed by 17.09 times.